139 related articles for article (PubMed ID: 9834001)
21. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643.
Obourn JD; Frame SR; Bell RH; Longnecker DS; Elliott GS; Cook JC
Toxicol Appl Pharmacol; 1997 Aug; 145(2):425-36. PubMed ID: 9266817
[TBL] [Abstract][Full Text] [Related]
22. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
[TBL] [Abstract][Full Text] [Related]
23. Specific binding of cholecystokinin, estradiol and somatostatin to human pancreatic cancer xenografts.
Singh P; Townsend CM; Poston GJ; Reubi JC
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):759-67. PubMed ID: 1683561
[TBL] [Abstract][Full Text] [Related]
24. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma.
Damgé C; Hajri A
Eur J Pharmacol; 1998 Apr; 347(1):77-86. PubMed ID: 9650851
[TBL] [Abstract][Full Text] [Related]
25. Modulation of cholecystokinin activity by albumin.
Huang SC; Talkad VD; Fortune KP; Jonnalagadda S; Severi C; Delle Fave G; Gardner JD
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10312-6. PubMed ID: 7479774
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic receptors for cholecystokinin: evidence for three receptor classes.
Yu DH; Huang SC; Wank SA; Mantey S; Gardner JD; Jensen RT
Am J Physiol; 1990 Jan; 258(1 Pt 1):G86-95. PubMed ID: 2301586
[TBL] [Abstract][Full Text] [Related]
27. Growth of azaserine-induced putative preneoplastic nodules in the rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
Ann N Y Acad Sci; 1994 Mar; 713():439-41. PubMed ID: 8018216
[No Abstract] [Full Text] [Related]
28. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells.
Smith JP; Rickabaugh CA; McLaughlin PJ; Zagon IS
Am J Physiol; 1993 Jul; 265(1 Pt 1):G149-55. PubMed ID: 8338163
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Talkad VD; Patto RJ; Metz DC; Turner RJ; Fortune KP; Bhat ST; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):103-16. PubMed ID: 7524683
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Jensen RT; Mantey SA; Bell RH
Gastroenterology; 1994 Oct; 107(4):1135-46. PubMed ID: 7523219
[TBL] [Abstract][Full Text] [Related]
31. Gastrin receptor expression during azaserine-induced rat pancreatic carcinogenesis.
Tsuei BJ; Povoski SP; Zhou W; Bell RH
J Surg Res; 1996 Jun; 63(1):105-9. PubMed ID: 8661181
[TBL] [Abstract][Full Text] [Related]
32. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
33. A reduced pancreatic protein secretion in response to cholecystokinin (CCK) in the obese Zucker rat correlates with a reduced receptor capacity for CCK.
Praissman M; Izzo RS
Endocrinology; 1986 Aug; 119(2):546-53. PubMed ID: 3015550
[TBL] [Abstract][Full Text] [Related]
34. Receptor-mediated internalization and secretion of cholecystokinin into rat pancreatic duct fluid.
Izzo RS; Praissman M
Am J Physiol; 1987 Oct; 253(4 Pt 1):G445-51. PubMed ID: 3661706
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of exocrine pancreatic insufficiency in streptozotocin-induced type 1 diabetes mellitus.
Patel R; Shervington A; Pariente JA; Martinez-Burgos MA; Salido GM; Adeghate E; Singh J
Ann N Y Acad Sci; 2006 Nov; 1084():71-88. PubMed ID: 17151294
[TBL] [Abstract][Full Text] [Related]
36. Internalization and cellular processing of cholecystokinin in rat pancreatic acinar cells.
Izzo RS; Pellecchia C; Praissman M
Am J Physiol; 1988 Dec; 255(6 Pt 1):G738-44. PubMed ID: 3202169
[TBL] [Abstract][Full Text] [Related]
37. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
Yule DI; Williams JA
Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
[TBL] [Abstract][Full Text] [Related]
38. High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion.
Tsunoda Y; Owyang C
Am J Physiol; 1995 Sep; 269(3 Pt 1):G435-44. PubMed ID: 7573455
[TBL] [Abstract][Full Text] [Related]
39. Cholecystokinin receptor occupation and cholecystokinin-induced calcium mobilization in the early phase in rat pancreatic acini.
Kusui T; Sato S; Katsushima S; Honda T; Shigeno C; Konishi J
Biochim Biophys Acta; 1991 Sep; 1094(2):231-7. PubMed ID: 1716460
[TBL] [Abstract][Full Text] [Related]
40. Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin.
Smith AJ; McKernan RM
Br J Pharmacol; 1999 Jan; 126(1):79-86. PubMed ID: 10051123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
